Dublin, March 19, 2024 (GLOBE NEWSWIRE) -- The "MRD Testing Market - Global and Regional Analysis: Focus on Technology, Target Detection, End User and Region Analysis - Analysis and Forecast, ...
Even when patients with acute myeloid leukemia (AML) appear to be in remission, small numbers of cancer cells can remain in the body. These lingering cells—known as measurable residual disease ...
BOULDER, Colo., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Foresight Diagnostics, a leader in ultra-sensitive minimal residual disease (MRD) detection technology, today announced the inclusion of circulating ...
SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine with annual revenues of $824 million, has announced the issuance of two ...
SEATTLE - Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a biotechnology company focused on understanding the adaptive immune system, announced that its clonoSEQ test for measurable residual ...
SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ:MYGN) has announced multiple research collaborations focusing on the application of molecular residual disease (MRD) testing in breast cancer management ...
FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (PSNL), a leader in advanced genomics for cancer, today announced the early access launch of Real-Time Variant Tracker, a powerful new option added ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results